$AVNW

Lake Street Remains a Buy on Aviat Networks (AVNW)

Lake Street analyst Jaeson Schmidt reiterated a Buy rating on Aviat Networks (AVNW) with a $31 price target. Roth MKM also maintained a Buy rating with a $38 target. AVNW reported Q2 revenue of $120.89M and a net loss of $1.28M, down from last year's profit. Insider sentiment is negative, with increased selling activity.

Original reporting
Published Sep 15, 2026, 1:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lake Street Remains a Buy on Aviat Networks (AVNW) — source image
Decision brief

The 30-second read

$AVNWNeutralLow
01

Why it matters

The reaffirmed ratings provide limited upside, while insider selling adds slight downside pressure. Overall impact on AVNW is expected to be modest.

02

Market read

Minor news with limited trading relevance; likely no significant price movement.

03

What to watch

No new earnings or guidance; market may already price in expectations.

Relevance 4/10Novelty 2/10Timing: today

Background

Lake Street analyst Jaeson Schmidt reiterated a Buy rating on Aviat Networks (AVNW) with a $31 price target; Roth MKM also maintained a Buy with $38 target. Recent quarterly results showed a slight revenue increase but a GAAP net loss, and insiders have been selling shares.

Company-level read

Ticker impact

$AVNWNeutralMedium confidence
Context

Lake Street reiterated a Buy rating and set a $31 price target; insider sold 629 shares for $12,385.

Expected impact

Limited short-term move, likely within a few percent.

Evidence & confidence

Rating unchanged and small insider sale provide minimal new catalyst.

Market effects

None

None

None

Counterpoint

Analyst reaffirmation may be overly optimistic given insider selling.

Key entities

  • Aviat Networks

    Provider of wireless transport solutions, ticker AVNW.

  • Lake Street

    Equity research firm issuing the Buy rating.

Related articles

$AVNWMedAI 8/10

Aviat Networks, Inc. Q4 2026 Earnings Call Summary

Aviat Networks reported six consecutive years of revenue growth, driven by a strategic shift and a $25M-$30M order from a U.S. Tier 1 customer. Q4 revenue in EMEA rose 53% due to private network wins. Gross margins faced pressure from component cost inflation, but the company plans price increases. Fiscal 2027 revenue guidance is $455M-$470M. Management highlighted growth opportunities in MDU, BEAD funding, and private networks. The company repurchased $2.2M in shares and has $420M in net operat

$AVNWMed

Aviat Networks Announces Fiscal 2026 Fourth Quarter and Twelve Months Financial Results

AVIAT NETWORKS, INC. (AVNW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Aviat Networks Announces Fiscal 2026 Fourth Quarter and Twelve Months Financial Results Fourth Quarter Total Revenue of $120.9 million Q4 Operating Income of $5.8 million; Q4 Non-GAAP Operating Income of $10.0 million Q4 Net Loss of $1.3 million; Q4 Adjusted EBITDA of $11.9 milli

$ORCLMedAI 8/10

Tencent Turns To Oracle Abroad For AI Chips

Tencent is reportedly using Oracle's overseas infrastructure for AI chips due to US export controls. A $7 billion contract could expand Oracle's cloud presence in Southeast Asia, potentially increasing data-center and power demand in the region.

$HPEHighAI 8/10

A $1.2B AI order landed September 30 - our models had this IT stock since July

Micron Technology Inc. (MU) reported stronger first-quarter forecasts due to high AI demand, with shares rising 5% after a $1.2B order for AMD (AMD) Helios AI Rack systems. InvestingPro's AI models identified several IT and energy stocks with significant gains, including Hewlett Packard Enterprise (HPE), which saw a 45.74% increase since July 2026. HPE's earnings beat expectations, with a 20.6% surprise and raised guidance to $3.35–$3.45 per share.

$LLYHighAI 8/10

Eli Lilly's Ebglyss Phase 3 Success Highlights Growth Potential

Eli Lilly (LLY) reported that its antibody therapy Ebglyss met primary endpoints in a Phase 3 trial for hand-and-foot atopic dermatitis, with 53% of patients showing significant improvement. The company submitted data to the FDA for label expansion. LLY is deemed modestly undervalued with a GF Value of $1561.18, a 25.9% margin of safety, and a GF Score of 96/100. Insiders sold $3.46B in shares over the past year.